The Research of Metabolomics on COPD

Guangzhou Institute of Respiratory Disease200 enrolled

Overview

Targeted metabolomics research was conducted on patients with chronic obstructive pulmonary disease (COPD). The correlation analyst between inflammation-related metabolites and lung function was analyzed by explored the metabolic pathways of inflammation-related omega-6 and omega-3 and combining them with lung function.

Based on the global initiative for chronic obstructive pulmonary disease, the 80 confirmed stable COPD patients with mild-to-moderate were involved, 80 COPD patients with severe and very severe, and age, sex, all matching 40 cases without lung disease. The participants information was collected. Whole blood and pulmonary function were examined at three time points: admission, six months and one year, at the same time, targeted metabolomic analysis method are applied to detect serum metabolites, According to the access to assess the different severity of COPD in the stable period and the level of metabolites in different admission periods. After that, correlation analysis was conducted with pulmonary function indicators and other clinical indicators to observe the research value of inflammation-related metabolites in the development of COPD.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Metabolomics Omega 6 Omega 3 COPD

Interventions

Lung function test was performed on the subjects with Jaeger lung function instrument of Germany.DIAGNOSTIC_TEST

This Jaeger lung function instrument of Germany is used to test the pulmonary ventilation function of COPD patients. Since the condition requires drug control and treatment, the drug cannot be stopped.

Agilent 1290 Infinity LC system (UHPLC, Santa Clara CA) was used for Targeted metabolite detection.DIAGNOSTIC_TEST

We used the Agilent 1290 Infinity LC system mass spectrometer to analyze and detect metabolite peaks of patients according to retention time and mass/charge ratio after preliminary experiments and derivatization.

Routine blood test

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * COPD diagnosis * The age ranges from 40 to 80 * No other pulmonary diseases * No immune-related diseases Exclusion Criteria: * Not consistent with COPD diagnosis * Age is out of range * Interstitial lung disease, asthma and other lung diseases * Immune system diseases * Lost to follow-up

Outcomes

Primary Outcomes

Forced expiratory volume in 1 second (FEV1)

The FEV1 percentage of predicted value is an important indicator in the diagnosis and treatment of COPD, and plays an important role in the severity rating. * level (mild) : FEV1 / FVC \< 70%, FEV1% pred \> 80%. Ⅱ level (moderate) : FEV1 / FVC \< 70%, 50% ≦ FEV1% pred\< 80%. Ⅲ level (severe) : FEV1 / FVC \< 70%, 30% ≦ FEV1% pred \< 50%. IV level (very severe) : FEV1/FVC\<70%, FEV1% pred \< 30%, or FEV1% pred \<50% with chronic respiratory failure.